+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats



Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats



Gastroenterology 132(2): 709-719



We studied whether administration of nitroflurbiprofen (HCT-1026), a cyclooxygenase inhibitor with nitric oxide (NO)-donating properties, modulates the increased intrahepatic vascular tone in portal hypertensive cirrhotic rats. In vivo hemodynamic measurements (n = 8/condition) and evaluation of the increased intrahepatic resistance by in situ perfusion (n = 5/condition) were performed in rats with thioacetamide-induced cirrhosis that received either nitroflurbiprofen (45 mg/kg), flurbiprofen (30 mg/kg, equimolar concentration to nitroflurbiprofen), or vehicle by intraperitoneal injection 24 hours and 1 hour prior to the measurements. Additionally, we evaluated the effect of acute administration of both drugs (250 micromol/L) on the intrahepatic vascular tone in the in situ perfused cirrhotic rat liver (endothelial dysfunction and hyperresponsiveness to methoxamine) and on hepatic stellate cell contraction in vitro. Typical systemic adverse effects of nonsteroidal anti-inflammatory drugs, such as gastrointestinal ulceration, renal insufficiency, and hepatotoxicity, were actively explored. In vivo, nitroflurbiprofen and flurbiprofen equally decreased portal pressure (8 +/- 0.8 and 8.4 +/- 0.1 mm Hg, respectively, vs 11.8 +/- 0.6 mm Hg) and reduced the total intrahepatic vascular resistance. Systemic hypotension was not aggravated in the different treatment groups (P = .291). In the perfused cirrhotic liver, both drugs improved endothelial dysfunction and hyperresponsiveness. This was associated with a decreased hepatic thromboxane A(2)-production and an increased intrahepatic nitrate/nitrite level. In vitro, nitroflurbiprofen, more than flurbiprofen, decreased hepatic stellate cells contraction. Flurbiprofen-treated rats showed severe gastrointestinal ulcerations (bleeding in 3/8 rats) and nefrotoxicity, which was not observed in nitroflurbiprofen-treated cirrhotic rats. Treatment with nitroflurbiprofen, an NO-releasing cyclooxygenase inhibitor, improves portal hypertension without major adverse effects in thioacetamide-induced cirrhotic rats by attenuating intrahepatic vascular resistance, endothelial dysfunction, and hepatic hyperreactivity to vasoconstrictors.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012997314

Download citation: RISBibTeXText

PMID: 17258737

DOI: 10.1053/j.gastro.2006.12.041


Related references

Vascular Hyporesponsiveness In Non-Cirrhotic Nafld-Induced Portal Hypertension: Role Of Nitric Oxide And Cyclooxygenase And Comparison With Other Models Of Pht. Journal of Hepatology 58: S513-S514, 2013

Influence of nitric oxide synthase and cyclooxygenase blockade on expression of cyclooxygenase and hemodynamics in rats with portal hypertension. Hepatobiliary and Pancreatic Diseases International 5(4): 564-569, 2006

Nitric oxide in pathogenesis of cirrhotic portal hypertension in rats and its hemodynamic effects. Zhonghua Wai Ke Za Zhi 36(5): 317-319, 1998

Tetrandrine ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats. Journal of Huazhong University of Science and Technology. Medical Sciences 24(4): 385-8 395, 2004

Salviae miltiorrhizae ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats. Hepatobiliary and Pancreatic Diseases International 2(3): 391-396, 2003

Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver. Digestive and Liver Disease 35(Suppl. 2): S61-S69, 2003

A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. Journal of Hepatology 39(6): 940-946, 2003

A liver-specific nitric oxide donor improves the intra-hepatic vascular response to increase portal blood flow and methoxamine in cirrhotic rats. Hepatology 38(4 Suppl 1): 176A, 2003

Differential effects of the nonsteroidal antiinflammatory drug flurbiprofen and its nitric oxide-releasing derivative, nitroflurbiprofen, on prostaglandin E(2), interleukin-1beta, and nitric oxide synthesis by activated microglia. Journal of Neuroscience Research 66(4): 715-722, 2001

Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. Journal of Clinical Investigation 100(3): 664-670, 1997

WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats. European Journal of Pharmacology 577(1-3): 100-108, 2007

Dose-dependent effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats. Journal Of Gastroenterology & Hepatology. 11(1): 1-6, 1996

The association between polymorphism of endothelial nitric oxide synthase gene and cirrhotic portal hypertension. Zhonghua Yi Xue Za Zhi 83(13): 1116-1121, 2003

Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension. Hepatology. 18(6): 1416-1421, 1993

Portal hypertension triggers peripheral signals that induces vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) expression at the intestinal microcirculation in cirrhotic rats. 2007